Bone Marrow & Stem Cell Transplant

Orca-T shows significant promise in reducing chronic graft-vs-host disease and improving survival rates in allogeneic transplant patients with hematologic malignancies.

During a live event, Nelson J. Chao, MD, discussed key outcomes from the trials supporting the use of ruxolitinib and axatilimab in patients with chronic graft-vs-host disease.

Explore the complexities of chronic GVHD symptoms, assessment, and innovative treatment strategies, including ruxolitinib and emerging therapies.

A groundbreaking trial shows promising survival rates and low GVHD in patients receiving mismatched stem cell transplants, expanding treatment options for diverse populations.

A novel combination therapy shows high response rates in relapsed DLBCL, enhancing eligibility for autologous stem cell transplantation.

New trial data reveals cyclophosphamide plus cyclosporin significantly enhances GVHD prevention in stem cell transplant patients, offering hope for better outcomes.

Jeremy S. Abramson, MD, discusses the significant 2-year follow-up results from the phase 3 STARGLO trial in DLBCL.

Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous therapies.

The safety and efficacy outcomes of a total of 3 CD19-directed CAR T-cell therapies were confirmed with other real-world data with CAR T-cell therapy in patients with B-cell malignancies.

Alfred L. Garfall, MD, provided a deep dive into the phase 2 BMT CTN 1902 trial of ide-cel in multiple myeloma after transplant.

A phase 3 trial did not support a transplant-based approach for patients who already achieved MRD negativity or a tandem transplant approach for those who did not achieve prior MRD negativity.

Transplantation improves survival after cladribine-based therapy for patients with relapsed/refractory acute myeloid leukemia, per phase 2 trial findings.

The resubmitted biologics license application for narsoplimab in transplant-associated thrombotic microangiopathy has been accepted by the FDA.

With the clinical hold on the tab-cel application lifted, phase 2 and 3 trials of the T-cell immunotherapy in patients with PTLD may resume.

Jeff Auletta, MD, discussed the ACCESS trial and explained that mismatched unrelated donor transplants can be a viable option.

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic graft-vs-host disease and reasons to select one over others.

The impact of physical and nutritional rehabilitation post bone marrow transplant in patients with hematologic malignancies will be determined in the REBOOT trial.

During a live event, Catherine J. Lee, MD, MS, discussed the efficacy and safety results of various trials of approved agents for treating chronic graft-vs-host disease.

During a live event, Catherine J. Lee, MD, MS, discussed the results of the AGAVE-201 trial.

Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T study.

Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with acute myeloid leukemia.

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

Two denosumab biosimilars have gained FDA approvals across multiple indications.

Uday R. Popat, MD, discusses the rationale behind evaluating itacitinib over other JAK inhibitors for graft-vs-host disease prophylaxis in a phase 2 study.

Uday R. Popat, MD, discusses a phase 2 trial exploring the use of itacitinib combined with post-transplant cyclophosphamide and tacrolimus to prevent graft-vs-host disease in patients undergoing a myeloablative fractionated busulfan regimen.